Outlook on the Future of Demodex Blepharitis Treatment

EP: 1.Overview of Demodex Blepharitis

EP: 2.Pathophysiology of Demodex Blepharitis

EP: 3.Diagnosing Demodex Blepharitis in Clinical Practice

EP: 4.Differential Diagnosis: Key Features of Demodex Blepharitis

EP: 5.Risk Factors and Mental Health Impact of Demodex Blepharitis

EP: 6.Treatment of Demodex Blepharitis

EP: 7.Diagnosis and Prevalence of Demodex Blepharitis

EP: 8.Exploring a Recently Approved Therapy for Demodex

EP: 9.Payer Approval + Alternate Treatments for Demodex Blepharitis

Now Viewing

EP: 10.Outlook on the Future of Demodex Blepharitis Treatment

EP: 11.Understanding Demodex Blepharitis Pathogenesis

EP: 12.Cost-Effective Medication Access in Demodex Blepharitis Treatment

EP: 13.Other Clinical Considerations in Demodex Blepharitis Treatment

This is a video synopsis/summary of an Insights involving Neda Shamie, MD.

With an FDA-approved treatment now available for Demodex blepharitis, it is hoped more eye care specialists will address this underlying problem that has chronically caused dry eye issues in patients without treatment. Breaking this cycle can create a scenario where no patients suffer from the chronicity of this disease anymore. The goal is to treat patients with the short 6-week course of Xdemvy(lotilaner ophthalmic solution 0.25%), only needing occasional yearly touch-up treatments depending on severity. Addressing this early prevents patients from developing chronic sequelae. 

This is one of the most exciting new treatment options available to eye care specialists, with exceptional clinical trial results that are truly groundbreaking, according to Shamie, who adds that it is rewarding to be part of a field making such advances to definitively treat conditions that were previously untouched.

Video synopsis is AI-generated and reviewed by AJMC® editorial staff.